

# Giacomo De Luca

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4936446/giacomo-de-luca-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

2,288  
citations

20  
h-index

47  
g-index

87  
ext. papers

3,074  
ext. citations

5.8  
avg, IF

5.22  
L-index

#	Paper	IF	Citations
75	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e325-e331	14.2	612
74	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49	3.9	270
73	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285	2.4	164
72	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e465-e473	14.2	130
71	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 428-36	5.3	102
70	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 526-35	5.3	91
69	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e253-e261	14.2	75
68	Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1046-1057	15.1	69
67	Arrhythmias in myocarditis: State of the art. <i>Heart Rhythm</i> , 2019, 16, 793-801	6.7	64
66	B cells in systemic sclerosis: a possible target for therapy. <i>Autoimmunity Reviews</i> , 2011, 10, 624-30	13.6	57
65	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 956-964	3.9	53
64	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233	8.4	32
63	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. <i>PLoS ONE</i> , 2016, 11, e0153012	3.7	31
62	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335	8.4	30
61	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019, 60, 46-53	3.9	29
60	Low prevalence of arrhythmias in clinically stable COVID-19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893	1.6	27
59	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819-820	8	26

58	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 54	5.7	25
57	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 57, e11-e12	3.9	24
56	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , <b>2021</b> , 133, 104071	3.7	21
55	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. <i>International Journal of Cardiology</i> , <b>2019</b> , 280, 110-116	3.2	20
54	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 675678	8.4	18
53	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. <i>Scandinavian Journal of Rheumatology</i> , <b>2017</b> , 46, 78-80	1.9	17
52	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , <b>2020</b> , 59, 171-175	3.9	17
51	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , <b>2017</b> , 239, 33	3.2	15
50	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 598308	5.6	14
49	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 17-25	3.9	13
48	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolimmunology</i> , <b>2018</b> , 7, e1440929	7.2	13
47	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. <i>Rheumatology</i> , <b>2020</b> , 59, 2523-2533	3.9	13
46	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 77, 9-17	3.9	12
45	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , <b>2018</b> , 265, 273-284	5.5	12
44	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. <i>Rheumatology</i> , <b>2015</b> , 54, 1991-9	3.9	11
43	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , <b>2020</b> , 59, 3731-3736	3.9	10
42	Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102330	15.5	10
41	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e143-e146	1.1	10

40	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 509-514	5.3	9
39	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> ,	2.4	9
38	Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. <i>JACC: Clinical Electrophysiology</i> , <b>2020</b> , 6, 1221-1234	4.6	8
37	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	8
36	Patient-reported outcome instruments in clinical trials of systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 90-102	2.3	8
35	Telemedicine in myocarditis: Evolution of a multidisciplinary "disease unit" at the time of COVID-19 pandemic. <i>American Heart Journal</i> , <b>2020</b> , 229, 121-126	4.9	8
34	Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	8
33	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 5028-5041	3.9	8
32	Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e113	2.4	7
31	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 653950	8.4	7
30	Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 288-292	8.4	7
29	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1-6	5.3	6
28	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 93, 87-94	3.9	6
27	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 24-32	2.3	5
26	The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	5
25	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 1-8	1.1	4
24	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	4
23	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use. <i>Journal of Clinical Rheumatology</i> , <b>2019</b> ,	1.1	4

22	Troponin in Stable Ischemic Heart Disease and Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1978-9	59.2	3
21	Mavrilimumab for severe COVID-19 - Authors' reply. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e662-e663	14.2	3
20	Gender-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study from the National Registry of the Italian Society Of Rheumatology. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	3
19	Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. <i>Rheumatology</i> , <b>2021</b> , 60, 465-467	3.9	3
18	Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , <b>2018</b> , 137, 2421-2422	16.7	2
17	A3.21 MicroRNA-34a and microRNA-155 in Systemic Sclerosis: possible epigenetic biomarkers of endothelial dysfunction in VEDOSS and long-standing disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A50.1-A50	2.4	2
16	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , <b>2021</b> , 138, 1554-1569	2.2	2
15	AB0621 GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS <b>2019</b> ,		2
14	A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 273-274		2
13	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , <b>2019</b> , 25, e140-e141	1.1	1
12	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1421-1422	4.1	1
11	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 131, 25-28	2.2	1
10	Successful use of cyclosporin A and interleukin-1 blockers combination in VEXAS syndrome: a single-centre case series.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5	1
9	Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging.. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> , 1	12.3	0
8	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.9	0
7	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102981	13.6	0
6	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1780-1784	4.1	0
5	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 77-86	1.1	0

4	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.. <i>Journal of Multidisciplinary Healthcare</i> , <b>2022</b> , 15, 815-824	2.8	o
3	Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on "Antisynthetase syndrome and cardiac involvement: a rare association" by Meudec et al. <i>Joint Bone Spine</i> 2018. doi: 10.1016/j.jbspin.2018.09.019. <i>Joint Bone Spine</i> , <b>2019</b> , 86, 407	2.9	
2	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> ,239719832210837	2.3	
1	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> ,	2.2	